[EPCA-2 in the early diagnosis of prostate cancer].
More and more clinical evidence has confirmed the limitations of the use of serum PSA in the screening, detection and treatment of prostate cancer, and scientists are continuously seeking for new biomarkers of the disease. The discovery of early prostate cancer antigen 2 (EPCA-2) has provided a new base for the screening, detection, treatment and follow-up of prostate cancer.
Yu
De-Shui
DS
Department of Urology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214023, China. ydsxinyi@163.com
Xu
Zhuo-Qun
ZQ
D000951:Antigens, Neoplasm / Q000032:analysis*; D042241:Early Diagnosis; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis*
D000951:Antigens, Neoplasm; C542166:early prostate cancer antigen-2, human